FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears

Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters. Thursday, the agency put out a notice citing “rare but serious” cases of stroke and tears in the lining of head and neck arteries.